Physician profile
Robert Morales
NPI 1538292693
$2,445.24
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $338 · 2021: $909 · 2022: $766 · 2023: $13.90 · 2024: $55.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $68.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $68.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $611.56 | 2019-2022 | |
| Lilly USA, LLC | $289.10 | 2020-2024 | Mounjaro |
| Janssen Pharmaceuticals, INC | $256.05 | 2019-2022 | |
| Amarin Pharma, INC. | $189.80 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $169.92 | 2019-2022 | |
| Pfizer INC. | $140.53 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $100.05 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $97.60 | 2019-2022 | |
| Amgen INC. | $94.85 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.16 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $74.44 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $57.47 | 2019-2020 | |
| Esperion Therapeutics, INC. | $54.66 | 2021 | |
| Dexcom, INC. | $54.53 | 2021-2022 | |
| Glaxosmithkline, LLC. | $49.14 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $29.87 | 2021 | |
| Abbott Laboratories | $23.20 | 2024 | Proclaim |
| Biogen, INC. | $21.86 | 2021 | |
| Almatica Pharma LLC | $19.50 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.72 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Morales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.